Myelodysplastic Syndromes (MDS)NCT07355478
Asia Myelodysplastic Syndrome (MDS) Registry
An observational study of Myelodysplastic Syndromes (MDS), run by Bristol-Myers Squibb at 3 sites in 3 countries.
Trial summary
The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Myelodysplastic Syndromes (MDS)
- What is being tested?
- Prescribed treatments for myelodysplastic syndromes (MDS)
- How many people
- 500 participants
- Where
- 3 sitesin 3 countries
- Study dates
- 11 Aug 2026to 30 Sep 2027
- How long will I take part?
- 2 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The registry will include adults who were/are newly diagnosed with myelodysplastic syndromes (MDS) in Asia (Singapore, South Korea and Taiwan).
Who may be able to join
- Retrospective enrolment of Myelodysplastic Syndrome (MDS) participants:
- Aged at least 18 years at initial diagnosis of MDS
- Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 January 2019 and 31 December 2022; and
- Diagnosed with MDS within 100 days from the date of diagnostic bone marrow (BM) aspirate
- Inclusion criteria for the prospective enrolment of MDS participants:
- Aged at least 18 years at initial diagnosis of MDS; and
- Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 October 2025 and 30 September 2026; and
- Diagnosed with MDS within 100 days from the date of diagnostic BM aspirate
Who cannot join
- None
Trial locations and contacts
3 sites in 3 countries. Contact the study team or a site near you to ask about taking part.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com contact
First line of the email MUST contain NCT # and Site #. contact
3 sites in 3 countries
Singapore1 site, 1 recruiting
- Recruiting
Singapore General Hospital
Singapore, 169608
Nurul Aidah, Site 0003
South Korea1 site, 1 recruiting
- Not yet recruiting
Local Institution - 002
Seoul, Seoul Teugbyeolsi, 03080
Site 002
Taiwan1 site, 1 recruiting
- Not yet recruiting
Local Institution - 0001
Taipei, 100229
Site 0001
About this study
The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.
- Conditions
- Myelodysplastic Syndromes (MDS)
- Being tested
- Prescribed treatments for myelodysplastic syndromes (MDS)
- Keywords
- Myelodysplastic syndromes (MDS)
- Medical subject headings
- Myelodysplastic Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Prescribed treatments for myelodysplastic syndromes (MDS)Drug
According to the product label
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Participants diagnosed with myelodysplastic syndromes (MDS) Receives: Drug: Prescribed treatments for myelodysplastic syndromes (MDS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Participant age
Measured: Baseline
Participant sex
Measured: Baseline
Participant race
Measured: Baseline
Participant weight
Measured: Baseline
Participant height
Measured: Baseline
Participant body mass index (BMI)
Measured: Baseline
Participant smoking status
Measured: Baseline
Participant drinking status
Measured: Baseline
Family history of MDS or other hematopoietic cancers
Measured: Baseline
Participant myelodysplastic syndromes diagnosis information
Measured: Baseline
Participant Eastern Cooperative Oncology Group (ECOG) Performance status at diagnosis
Measured: Baseline
Participant comorbidities at diagnosis
Measured: Baseline
Participant Charlson comorbidity index (CCI) score at diagnosis
Measured: Baseline
Prior clinical diagnosis of other cancers
Measured: Baseline
Prior clinical diagnosis of hematological diseases
Measured: Baseline
Anemia status at diagnosis
Measured: Bseline
Thrombocytopenia status at diagnosis
Measured: Baseline
Neutropenia status at diagnosis
Measured: Baseline
Iron overload status at diagnosis
Measured: Baseline
Red blood cell (RBC) transfusion dependence status at diagnosis
Measured: Baseline
International Prognostic Scoring System (IPSS) score at diagnosis
Measured: Baseline
Revised International Prognostic Scoring System (IPSS-R) score at diagnosis
Measured: Baseline
Molecular International Prognostic Scoring System (IPSS-M) score at diagnosis
Measured: Baseline
Bone marrow aspirate results
Measured: Baseline and up to 2-years
Presence of dysplasia
Measured: Baseline and up to 2-years
Cytogenetic test results
Measured: Baseline and up to 2-years
Mutation test results at diagnosis
Measured: Baseline
Complete blood count test results at diagnosis
Measured: Baseline
Mean corpuscular volume (MCV)
Measured: Baseline and up to 2-years
C-reactive protein (CRP)
Measured: Baseline and up to 2-years
Serum ferritin (SF) level
Measured: Baseline and up to 2-years
Serum erythropoietin levels
Measured: Baseline and up to 2-years
Lactate dehydrogenase (LDH)
Measured: Baseline and up to 2-years
Secondary outcomes (12)
Initial treatment received following diagnosis
Measured: Baseline
Prior treatments and concomitant medications received
Measured: Baseline
Subsequent treatments received
Measured: Up to 2-years
Time from diagnosis to treatment initiation
Measured: Baseline
Treatment duration
Measured: Up to 2-years
Real-world overall survival (rwOS)
Measured: Baseline and up to 2-years
Time to disease-risk progression (per IPSS-R)
Measured: Baseline and up to 2-years
Time to acute myeloid leukemia (AML) progression
Measured: Baseline and up to 2-years
Time to iron overload
Measured: Baseline and up to 2-years
Overall response rate (ORR)
Measured: Baseline and up to 2-years
Duration of response (DOR)
Measured: Baseline and up to 2-years
Real-world relapse-free survival (rwRFS)
Measured: Baseline and up to 2-years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jan 2026
- Study start11 Aug 2026
- Primary completion31 Oct 2026 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myelodysplastic Syndromes (MDS)Studies of the same condition, open and under way.
- More trials run by Bristol-Myers SquibbThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 500 participants (estimated)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bristol Myers Squibb, Study director, Bristol-Myers SquibbBristol-Myers Squibb, Study director, Bristol-Myers Squibb
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07355478
- Sponsor's protocol ID
- CA056-1131
- Status last verified
- Oct 2026
- First submitted
- 28 Nov 2025
- Last updated
- 8 Oct 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No